Cargando…

Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018

We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally s...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Amy M., Kugeler, Kiersten J., Nelson, Christina A., Marx, Grace E., Hinckley, Alison F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853566/
https://www.ncbi.nlm.nih.gov/pubmed/33496238
http://dx.doi.org/10.3201/eid2702.202728
_version_ 1783645988950376448
author Schwartz, Amy M.
Kugeler, Kiersten J.
Nelson, Christina A.
Marx, Grace E.
Hinckley, Alison F.
author_facet Schwartz, Amy M.
Kugeler, Kiersten J.
Nelson, Christina A.
Marx, Grace E.
Hinckley, Alison F.
author_sort Schwartz, Amy M.
collection PubMed
description We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally stable, despite fluctuations in the number of enrollees. Annual incidence of Lyme disease diagnoses per 100,000 enrollees ranged from 49 to 88, ≈6–8 times higher than that observed for cases reported through notifiable disease surveillance. Age and sex distributions among Lyme disease diagnoses in MarketScan were similar to those of cases reported through surveillance, but proportionally more diagnoses occurred outside of peak summer months, among female enrollees, and outside high-incidence states. Misdiagnoses, particularly in low-incidence states, may account for some of the observed epidemiologic differences. Commercial claims provide a stable data source to monitor trends in Lyme disease diagnoses, but certain important characteristics warrant further investigation.
format Online
Article
Text
id pubmed-7853566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-78535662021-02-09 Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018 Schwartz, Amy M. Kugeler, Kiersten J. Nelson, Christina A. Marx, Grace E. Hinckley, Alison F. Emerg Infect Dis Research We evaluated MarketScan, a large commercial insurance claims database, for its potential use as a stable and consistent source of information on Lyme disease diagnoses in the United States. The age, sex, and geographic composition of the enrolled population during 2010–2018 remained proportionally stable, despite fluctuations in the number of enrollees. Annual incidence of Lyme disease diagnoses per 100,000 enrollees ranged from 49 to 88, ≈6–8 times higher than that observed for cases reported through notifiable disease surveillance. Age and sex distributions among Lyme disease diagnoses in MarketScan were similar to those of cases reported through surveillance, but proportionally more diagnoses occurred outside of peak summer months, among female enrollees, and outside high-incidence states. Misdiagnoses, particularly in low-incidence states, may account for some of the observed epidemiologic differences. Commercial claims provide a stable data source to monitor trends in Lyme disease diagnoses, but certain important characteristics warrant further investigation. Centers for Disease Control and Prevention 2021-02 /pmc/articles/PMC7853566/ /pubmed/33496238 http://dx.doi.org/10.3201/eid2702.202728 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Schwartz, Amy M.
Kugeler, Kiersten J.
Nelson, Christina A.
Marx, Grace E.
Hinckley, Alison F.
Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title_full Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title_fullStr Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title_full_unstemmed Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title_short Use of Commercial Claims Data for Evaluating Trends in Lyme Disease Diagnoses, United States, 2010–2018
title_sort use of commercial claims data for evaluating trends in lyme disease diagnoses, united states, 2010–2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853566/
https://www.ncbi.nlm.nih.gov/pubmed/33496238
http://dx.doi.org/10.3201/eid2702.202728
work_keys_str_mv AT schwartzamym useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018
AT kugelerkierstenj useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018
AT nelsonchristinaa useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018
AT marxgracee useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018
AT hinckleyalisonf useofcommercialclaimsdataforevaluatingtrendsinlymediseasediagnosesunitedstates20102018